Form 4: Gossamer Bio Director, John D. Quisel, Acquires 115,000 Stock Options

Director John D. Quisel acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024.

Summary

• On June 6, 2024, John D. Quisel, a director of Gossamer Bio, Inc., acquired 115,000 non-qualified stock options.
• The options were granted as part of the Non-Employee Director Compensation Program.
• The exercise price of the options is $0.60.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service on the board.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation, indicating standard corporate governance practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes continued service on the board of directors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in corporate governance to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options to incentivize performance and align interests with shareholders.
• The vesting schedule described is typical, with vesting tied to continued service on the board.

Stakeholder Impact

• The acquisition of stock options by a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates